These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 22126494)

  • 1. Survival analysis of women with breast cancer under adjuvant therapy in South India.
    Venkatesan P; Raman TT; Ponnuraja C
    Asian Pac J Cancer Prev; 2011; 12(6):1533-5. PubMed ID: 22126494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
    Mook S; Schmidt MK; Rutgers EJ; van de Velde AO; Visser O; Rutgers SM; Armstrong N; van't Veer LJ; Ravdin PM
    Lancet Oncol; 2009 Nov; 10(11):1070-6. PubMed ID: 19801202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
    Jara Sánchez C; Ruiz A; Martín M; Antón A; Munárriz B; Plazaola A; Schneider J; Martínez del Prado P; Alba E; Fernández-Aramburo A
    Breast Cancer Res Treat; 2007 Jan; 101(2):215-23. PubMed ID: 16823507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.
    Owusu C; Lash TL; Silliman RA
    Breast J; 2007; 13(4):374-82. PubMed ID: 17593042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.
    Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP
    Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
    Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
    Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
    Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
    Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
    Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
    J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adjuvant chemotherapy on recurrence-free survival varies by neo-adjuvant treatment in patients with stage III rectal cancer.
    van Erning FN; Rutten HJ; van den Berg HA; Lemmens VE; van Halteren HK
    Eur J Surg Oncol; 2015 Dec; 41(12):1630-5. PubMed ID: 26437853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
    Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
    Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
    Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
    Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer.
    Abdel-Fatah TM; Ball G; Lee AH; Pinder S; MacMilan RD; Cornford E; Moseley PM; Silverman R; Price J; Latham B; Palmer D; Chan A; Ellis IO; Chan SY
    Clin Cancer Res; 2015 Mar; 21(5):1052-62. PubMed ID: 25520390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the correlation between hospital of primary treatment and the survival of women with breast cancer.
    Hébert-Croteau N; Brisson J; Lemaire J; Latreille J; Pineault R
    Cancer; 2005 Oct; 104(7):1343-8. PubMed ID: 16080144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cure models for estimating hospital-based breast cancer survival.
    Rama R; Swaminathan R; Venkatesan P
    Asian Pac J Cancer Prev; 2010; 11(2):387-91. PubMed ID: 20843121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.